Form 8-K Bausch & Lomb Corp For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at BofA Securities on new acquisition
July 3, 2023 6:53 AM EDTBofA Securities analyst Craig Bijou raised the price target on Bausch & Lomb Corp. (NYSE: BLCO) to $23.00 (from $19.00) while maintaining a Buy rating.
The analyst is positive on the acquisition of Novartis dry eye disease (DED) drug.
"We see the deal as a meaningful... More
Bausch + Lomb Corporation (BLCO) shares surge on $2.5bn deal to acquire XIIDRA
June 30, 2023 11:19 AM EDTBausch + Lomb Corporation (NYSE: BLCO) shares surged Friday after the company announced a deal to acquire XIIDRA from Novartis for up to $2.5 billion.
BLCO shares are currently up more than 5% at $20.20 after initially hitting a high of $21.95 per share.
The company, through an affiliate, will acquire XIIDRA, libvatrep, and AcuStream in a deal worth up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up... More
